Imiquimod/Zalifrelimab

咪喹莫特/泽弗利单抗

Report date: 2025/07/25 10:36:04

Base Information

Drug NameImiquimod/Zalifrelimab
Drug Alias NameImiquimod+ZalifrelimabUGN-302UGN-201+UGN-301
ClassificationBiologics
Mechanisms of ActionToll like receptor 7 agonistsToll like receptor 8 agonistsAnti-CTLA4
TargetsToll like receptor 7Toll like receptor 8Cytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsUrinary Bladder Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes ZalifrelimabImiquimod
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUrogen Pharma
China Registration ClassN/A

Develop Information

Active CompaniesUrogen Pharma
Inactive CompaniesN/A
Active IndicationsUrinary Bladder Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A